LncRNA ADAMTS9-AS1 knockdown suppresses cell proliferation and migration in glioma via down-regulating Wnt/β-catenin signaling pathway

Abstract

The long non‐coding RNA antisense 1 ADAMTS9-AS1 has been reported to serve as an oncogene or tumor suppressor in several tumors, including colorectal cancer and hepatocellular carcinoma. Nevertheless, the clinical significance and biological behaviors of ADAMTS9-AS1 in glioma still remain unclear. Therefore, the goal of this study was to evaluate the functional roles and potential mechanisms of ADAMTS9-AS1 in glioma cells. Using quantitative real-time PCR analysis, we found that ADAMTS9-AS1 was upregulated in glioma tissues and cells in comparison to corresponding controls. ADAMTS9-AS1 expression level was correlated to tumor size (p=0.005) and WHO grade (p=0.002). Kaplan-Meier analysis and Cox multivariate analysis showed that ADAMTS9-AS1 could serve as an independent prognostic factor affecting the overall survival of glioma patients. Functionally, depletion of ADAMTS9-AS1 significantly suppressed the proliferation, migration and invasion in glioma cell lines (U251 and U87), as shown via CCK-8 assay, Edu corporation assay, wound healing assay and transwell assay. Furthermore, we demonstrated that knockdown of ADAMTS9-AS1 suppressed Wnt1, β-catenin, c-myc and PCNA, while upregulating E-cadherin expression. In conclusion, our data revealed that ADAMTS9-AS1 confers oncogenic function in the progression of glioma, thus targeting ADAMTS9-AS1 might be a promising therapeutic strategy for this disease.

Mechanisms of long non-coding RNAs in biological phenotypes and ferroptosis of glioma

“…Another important molecular pathway activated during the development of human cancers, including glioma, is the Wnt/β-catenin signaling pathway ( 31 , 32 ). LncRNA ADAMTS9-AS1 was confirmed to be involved in the positive regulation of Wnt/β-catenin signaling pathway in glioma, leading to glioma cell proliferation ( 25 ). Zhou et al.…”